Sort
50,496 grants matching “lung cancer”
CANOE Partnership: Cancer Awareness, Navigation, Outreach, and Equitable Indigenous Health Outcomes
$2,483,619Lonnie A. Nelson · Fred Hutchinson Cancer Center · U19 · FY2024 · MD
CALIFORNIA TEACHERS STUDY
$2,482,687Leslie Bernstein · Beckman Research Institute/City Of Hope · R01 · FY2008 · CA
(EET Biobank) NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank
$2,481,702Kathleen Nicol · Research Inst Nationwide Children'S Hosp · U24 · FY2022 · CA
SPORE in Lung Cancer
$2,480,919Vanderbilt University · P50 · FY2002 · CA
OTHER FUNCTIONS SBIR PHASE II TOPIC 275, GENERIC ERBITUX FOR TREATMENT OF EGFR+
$2,479,561Peisheng Hu · Cancer Therapeutics Laboratories, Inc. · N44 · FY2012 · CA
ETIB Clinical Research Core
$2,479,411Ronald Gress · Division Of Basic Sciences - Nci · ZID · FY2011 · CA
ETIB Clinical Trials
$2,479,411Ronald Gress · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Translational Studies in FLASH Particle Radiotherapy
$2,478,484Constantinos Koumenis · University Of Pennsylvania · P01 · FY2022 · CA
Studies of Populations Exposed to Occupational Sources of Radiation
$2,475,812Cari Kitahara · Division Of Cancer Epidemiology And Genetics · ZIA · FY2023 · CA
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network
$2,475,134Janet Ellen Dancey · Queen'S University At Kingston · U10 · FY2020 · CA
The Role of TIMPs in Cell Growth and Differentiation: Tumor Angiogenesis
$2,474,858William G Stetler-Stevenson · Division Of Clinical Sciences - Nci · Z01 · FY2008 · CA
CCR Genomics Core
$2,473,796Elizabeth Conner · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA
Cancer Risk in Human Populations
$2,471,847Debra Silverman · Division Of Cancer Epidemiology And Genetics · ZIA · FY2018 · CA
Fred Hutchinson Cancer Center Lung SPORE
$2,471,718A. McGarry Houghton · Fred Hutchinson Cancer Center · P50 · FY2025 · CA
Genetic and Biochemical Approaches to Tyrosine Kinase and Lymphocyte Signaling
$2,471,222Pamela Schwartzberg · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
OPTIMIZATION OF HIGH DOSE CONFORMAL THERAPY
$2,470,329University Of Michigan At Ann Arbor · P01 · FY2004 · CA
Biology of Long-Term Mechanical Circulatory Support
$2,469,779Yoshifumi Naka · Columbia University Health Sciences · P50 · FY2008 · HL
SPORE in Lung Cancer
$2,468,469Vanderbilt University · P50 · FY2005 · CA
Molecular Diagnostics Core Laboratory
$2,468,096Liqiang Xi · Division Of Basic Sciences - Nci · ZIC · FY2019 · CA
(EET Biobank) NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank
$2,467,614Kathleen Nicol · Research Inst Nationwide Children'S Hosp · U24 · FY2023 · CA
Center for Pre-Clinical Cancer Research
$2,467,250Joseph Francis · Louisiana State Univ A&M Col Baton Rouge · P20 · FY2021 · GM
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network: Clinical Trials Development & Member Site Core
$2,466,309Janet Ellen Dancey · Queen'S University At Kingston · U10 · FY2020 · CA
Genome Transplant Dynamics: non-invasive sequencing-based diagnosis of rejection
$2,463,942Hannah Augusta Valantine · Stanford University · RC4 · FY2010 · AI
Barrett's Esophagus: Predictors of Progression
$2,462,800Brian J Reid · Fred Hutchinson Cancer Research Center · P01 · FY2015 · CA
THE PRIMARY RISK FACTOR LIMITING THE AMOUNT OF TIME AN ASTRONAUT CAN SPEND IN FLIGHT IS THE RISK OF CANCER INDUCTION RESULTING FROM THE UNIQUE RADIATIONS INHERENT TO THE DEEP SPACE ENVIRONMENT. ONE STRATEGY FOR MITIGATING RADIATION INDUCED CARCINOGENESIS IS TO PROVIDE BIOLOGICAL COUNTERMEASURES THAT MITIGATE RADIATION INJURY AND CANCER INDUCTION. TO DATE THE ONLY FDA APPROVED RADIOPROTECTOR IS THE FREE RADICAL SCAVENGER AMIFOSTINE; HOWEVER CONCERNS ABOUT TOXICITY AND REPORTS OF SEVERE ANAPHYLACTIC REACTIONS TO THIS DRUG PREVENT ITS USE IN SPACEFLIGHT. THEREFORE THERE IS A NEED TO DETERMINE AND VALIDATE APPROPRIATE BIOLOGICAL COUNTERMEASURES TO MITIGATE SPACE RADIATION CARCINOGENESIS THEREBY INCREASING THE AMOUNT OF TIME ASTRONAUTS CAN SAFELY SPEND IN SPACE. IN THE PROPOSED STUDIES WE WILL EVALUATE THE RADIO PROTECTIVE POTENTIAL OF GC4419 A NOVEL SUPEROXIDE DISMUTASE MIMETIC DEVELOPED BY GALERA THERAPUTICS (ST. LOUIS MO) IN MITIGATING SPACE RADIATION CARCINOGENESIS. DUE TO ITS EFFICACY IN PHASE 1 CLINICAL TRIALS AND PRE-CLINICAL DATA GENERATED BY OUR GROUP GC4419 IS CURRENTLY BEING FAST TRACKED INTO FDA PHASE II HUMAN CLINICAL TRIALS AS A RADIOPROTECTOR FOR PATIENTS UNDERGOING CHEMORADIATION THERAPY FOR THE TREATMENT OF HEAD AND NECK CANCER. NOT ONLY DOES GC4419 REDUCE THE FREQUENCY OF RADIATION INDUCED ADVERSE EFFECTS PRE-CLINICAL DATA SUGGEST IT HAS POTENT ANTI-CARCINOGENIC AND ANTI-TUMOR EFFECTS AS WELL. THEREFORE GC4419 REPRESENTS A SAFE CLINICALLY TESTED COUNTERMEASURE TO REDUCE RADIATION INJURY. IN THE PROPOSED STUDIES WE WILL EVALUATE THE EFFICACY OF GC4419 IN PREVENTING SPACE RADIATION INDUCED CARCINOGENESIS FOCUSING SPECIFICALLY ON THE LUNG AS A PRIMARY TUMOR SITE.
$2,461,498The University Of Texas Southwestern Medical Center · · FY2020 · National Aeronautics and Space Administration